ReviewEuropean heart journal2022
Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias.
Review in European heart journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 65 citations in OpenAlex.
- Cardiac Sympathetic Neuromodulation in the Management of Refractory Electrical Storm: A Narrative Review.Journal of clinical medicine · 2026Review
- Multimodal, device-based therapeutic targeting of the cardiovascular autonomic nervous system.Nature reviews. Cardiology · 2026Review
- Breakthrough ventricular fibrillation in a patient with catecholaminergic polymorphic ventricular tachycardia after a decade of stability: A follow-up report.HeartRhythm case reports · 2026Article
- Gene therapy for cardiac arrhythmias.Nature reviews. Cardiology · 2026Review
- Polymorphic ventricular tachycardia with mutation in KCNJ2: case report.Frontiers in cardiovascular medicine · 2026Article
- Enhanced Neuromodulation Using PC-CNTs and NIR Photothermal Therapy for Preventing Ventricular Arrhythmias.International journal of nanomedicine · 2026Article
- Implantable cardioverter defibrillators for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia? (Not so fast, Louis).Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- TP-fusion at peak exercise: a novel marker for the recognition of unsuspected long QT syndrome patients.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- Electrophysiological comparison of left versus right stellate ganglia neurons.Journal of molecular and cellular cardiology plus · 2025Article
- Application of stereotactic radiotherapy in the treatment of cardiovascular diseases through sympathectomy.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Review
- Cardiac Channelopathies: Clinical Diagnosis and Promising Therapeutics.Journal of the American Heart Association · 2025Review
- Genetics, manifestations, and management of catecholaminergic polymorphic ventricular tachycardia.Current opinion in cardiology · 2025Review
- Stellate Ganglia: A Key Therapeutic Target for Malignant Ventricular Arrhythmia in Heart Disease.Circulation research · 2025Review
- Induced Pluripotent Stem Cells in Congenital Long QT Syndrome: Research Progress and Clinical Applications.Reviews in cardiovascular medicine · 2025Review
- Unicentric Brazilian registry of cardiac sympathetic denervation for control of ventricular arrhythmias.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2025Article
- Managing long QT syndrome patients, cooking, and common sense.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Impact of self-directed e-learning on nurses' competency in arrhythmia interpretation in cardiology.PloS one · 2025Article
- Autophagy-enhanced nanosonosensitizer mediated sonodynamic therapy for post-myocardial infarction neuromodulation and arrhythmia prevention.Theranostics · 2025Article
- Treatment Outcomes in Children With Catecholaminergic Polymorphic Ventricular Tachycardia: A Single Institutional Experience.Korean circulation journal · 2024Article
- Torsades de Pointes electrical storm in children with KCNH2 mutations.BMC medical genomics · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proper management of patients affected by genetic disorders causing life-threatening arrhythmias is important for several reasons, including even societal ones, given the predominantly young age of those affected. Incorrect management often has dire consequences, ranging from unnecessary psychologic damage for the patients whose life becomes too limited by the fear of sudden death to equally avoidable tragedies when the entire armamentarium of effective therapies is not fully utilized. In this review, we focus primarily on long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) and deal specifically with the clinical impact of the most commonly used cardiac sympathetic denervation (CSD), namely left cardiac sympathetic denervation (LCSD). The two of us have used LCSD in the management of our patients with either LQTS or CPVT for a very long time and have been involved in ∼500 such interventions. It is on the basis of this personal and direct experience that we wish to share our views with clinical cardiologists and electrophysiologists, adult and paediatric, and with genetic cardiologists. We will begin by reviewing the history and rationale underlying sympathetic denervation therapy and will continue with a disease-specific intensification of therapy, and then with a discussion on how the impressive efficacy of LCSD should translate into guideline-directed therapy in both current and future guidelines, in order to upgrade the quality of care in the era of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.